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ABSTRACT 
Introduction 
 Varying practices for oral chemotherapy prescription and administration in the inpatient 
setting led to a need for a standardized process. The Iowa Model of Evidenced-Based Practice to 
Improve Quality Care was used as a framework to guide the project and establish a standardized 
process. Thus, the purpose of this project was to standardize the prescription and administration 
of oral chemotherapy throughout the Hawai`i Pacific Health (HPH) healthcare system in a 
manner that complies with the American Society of Clinical Oncology (ASCO) and the 
Oncology Nursing Society (ONS) Chemotherapy Administration standards. 
Methods 
 The practice change included an algorithm that standardized the process for oral 
chemotherapy prescription by requiring orders to be prescribed by an appropriate specialty 
prescriber. Non-specialty prescribers were considered appropriate prescribers when ordering 
antiandrogens, aromatase inhibitors, and selective estrogen receptor modulators that meet 
specific criteria and are screened by a pharmacist. The administration process included the 
integration of a chemotherapy-competent nurse for the first dose administration to ensure patient 
and staff education. Additionally, a SMART phase was created for standardized nursing 
documentation.  
Results 
 The new oral chemotherapy prescription and administration process was successfully 
implemented. The average monthly volume of oral chemotherapy orders decreased during the 
implementation phase although the overall volume for oncology services remained consistent. At 
baseline, the average number of doses was 13 per month. After implementation, the average 
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decreased by 70% to four per month. Appropriate specialty-provider prescribing of oral 
chemotherapy increased from 7% to 64%, administration by a chemotherapy-competent nurse 
increased from 5% to 64%, and patient education at first administration increased from 9% to 
55%.  
Discussion 
 Implementation of the project to standardize the process oral chemotherapy prescription 
and administration resulted in and higher quality care for patients receiving oral chemotherapy in 
the inpatient setting at SMC. Results revealed project objectives were met with an increased 
compliance in prescription, administration, and education for oral chemotherapy orders.  
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CHAPTER 1. EXECUTIVE SUMMARY 
Introduction 
 Over the last decade, the use of oral chemotherapy for the treatment of cancer has 
dramatically increased, with more than 25% of new antineoplastic drugs being developed for oral 
administration (Bourmaud et al., 2014). Oral chemotherapies have similar toxicities to their 
parenteral counterparts; however, standards of safety and monitoring are less rigorous, despite 
many of the same safety concerns. Although most institutions have strict guidelines for the 
administration of parenteral chemotherapy, similar protocols generally do not exist for oral 
chemotherapy (Shah et al., 2016). The purpose of this evidence-based (EB) project is to 
standardize the process for prescribing and administering oral chemotherapy in a manner that 
complies with the American Society of Clinical Oncology (ASCO) and with the Oncology 
Nursing Society (ONS) Chemotherapy Administration at Hawai`i Pacific Health (HPH) 
healthcare system.  
Conceptual Framework 
 The Iowa Model of Evidence-Based Practice was used as a framework for this EB 
practice change, aiming to standardize the process for inpatient oral chemotherapy prescription 
and administration at Straub Medical Center (SMC), a facility within the HPH healthcare system. 
The Iowa Model involves a systematic stepwise process that guides program development 
though: 1) Identifying triggers, 2) Forming a team, 3) Assembling research, 4) Critiquing and 
synthesize research, 5) Piloting an EB practice change, 6) Implementing an EB practice change, 
7) Monitoring and analyzing structure, process, and outcome data (Titler et al., 2001).  
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Literature Review and Synthesis 
 An electronic search of the literature was completed using CINAHL with Full Text, 
PubMed, the Cochrane Library, and the National Guideline Clearinghouse databases. The 
majority of applicable results were obtained from CINAHL and PubMed.  Some key search 
terms included “oral chemotherapy”, “neoplasms/drug therapy”, "administration, oral”, 
"antineoplastic protocols", “electronic prescribing”, “computerized provider order entry”, and 
“inpatients”. This project included 25 journal articles and three clinical practice guidelines. 
While overall adoption is currently lagging for oral chemotherapy, evaluation of the literature 
indicated that the ASCO/ONS guidelines should be followed and implemented at all facilities.  
Innovations & Objectives 
 Based on the literature, an EB project was developed to standardize the process of oral 
chemotherapy prescription and administration by implementing a process algorithm. The 
practice change included an algorithm that standardized the process for oral chemotherapy 
prescription by requiring orders to be prescribed by an appropriate specialty prescriber. Non-
specialty prescribers were considered appropriate prescribers when ordering antiandrogens, 
aromatase inhibitors, and selective estrogen receptor modulators that met specific criteria and 
were screened by a pharmacist. The administration process included the integration of a 
chemotherapy-competent nurse for the first dose administration to ensure patient and staff 
education. Additionally, a SMART phrase was created for standardized nursing documentation. 
Methods 
 The HPH healthcare system includes four major hospitals: SMC Kapi`olani, Pali Momi, 
and Wilcox. The standardized process aimed for system wide implementation, but was initially 
implemented at SMC due to its high volume of oral chemotherapy orders and low compliance 
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with chemotherapy prescribing and administration policy. Baseline data was collected from June 
2016 to December 2016. The sample was oral chemotherapy orders prescribed to inpatients on 
the 3rd, 4th, and 5th, floors at SMC from October 2017 to December 2017. Data was collected 
monthly via the EMR system and a retrospective chart review was completed. 
Results 
 The oral chemotherapy prescription and administration process was successfully 
implemented at SMC. The average monthly volume of oral chemotherapy orders decreased 
during the implementation phase although the overall volume for oncology services remained 
consistent. At baseline, the average number of doses was 13 per month. At post implementation, 
the average decreased by 70% to four per month. Appropriate specialty-provider prescribing of 
oral chemotherapy increased from 7% to 64%; administration by a chemotherapy-competent 
nurse increased from 5% to 64%; and patient education at first administration increased from 9% 
to 55%.  
Discussion 
 Implementing an algorithm to standardize the process of oral chemotherapy prescribing 
and administration resulted in higher quality care for patients receiving oral chemotherapy in the 
inpatient setting at SMC. Results revealed project objectives were met with an increase in 
prescribing and administering oral chemotherapy that complies with facility policy, and 
ASCO/ONS Chemotherapy. Implementing the algorithm decreased the volume of orders, 
increased the number prescribed by an appropriate specialty, increased the number administered 
by a chemotherapy-competent nurse, and increased the number of patients that received 
education. 
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CHAPTER TWO. PROBLEM 
Introduction 
 Oral chemotherapy is fast becoming a common treatment option, with more than 25% of 
new antineoplastic drugs being developed for oral administration (Bourmaud et al., 2014). 
Although oral chemotherapy carries several benefits and conveniences, the rapid increase has 
created a unique set of challenges as the safeguards that have evolved over time for parenteral 
chemotherapy are lacking for orals. The purpose of this EB project is to standardize the process 
for prescribing and administering oral chemotherapy in a manner that complies with facility 
policy, with the ASCO/ONS standards Chemotherapy Administration standards in the inpatient 
setting at the SMC, a facility within the HPH system. This chapter will present the background of 
the problem, a conceptual model, and a literature review.   
Background and Problem 
 Although traditional oncology treatments have mainly focused on the parenteral 
administration of chemotherapy, oral chemotherapy is fast becoming a viable option for cancer 
treatment. Oral chemotherapy drugs have been available for decades and the number of oral 
chemotherapy agents approved by the United States (US) Food and Drug Administration has 
increased significantly in recent years (Weingart et al., 2012). In 2013 alone, five of eight newly 
approved cancer therapies were in an oral formulation and the use of oral chemotherapy agents 
will continue to increase as more agents enter the market (Anders, Shillingburg, & Newton, 
2015). Experts predict that this trend will continue, with the National Comprehensive Cancer 
Network task force (NCCN) estimating that more than a quarter of the approximately 400 
antineoplastic agents in development will be administered orally (Weingart et al., 2012). 
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 As oral chemotherapy is emerging as a new treatment option for well-selected patients, it 
is shifting the paradigm in cancer care. Oral chemotherapy can be self-administered at home, 
allowing for convenience, however home therapy also transfers responsibility for the 
management and monitoring to patients, their caregivers, and healthcare professionals who may 
not have the appropriate training to take on these new tasks (The Institute for Safe Medication 
Practices Canada, 2015). 
 Medication errors are a long-standing concern with regard to the administration of 
chemotherapy. In recent years, a rigorous set of checks and balances has been implemented for 
ordering and administrating parenteral chemotherapy to include templated orders, electronic 
order-entry systems, clinician double-checks, and review by at least three or four licensed health 
care providers. To date, however, fewer controls are integrated into oral chemotherapy protocols 
(Weingart et al., 2008).   
 A 2007 survey, conducted by Weingart and colleagues, reviewed 54 US comprehensive 
cancer centers’ safety practices, finding that, in comparison to parenteral chemotherapy, fewer 
safety standards for oral chemotherapy agents had been adopted. Only one in four centers had 
standard prescribing safeguards in place for oral chemotherapies, and fewer than one in five had 
measures to ensure safe administration and monitoring. Additionally, oral chemotherapy lacked 
guidelines and standards for prescription, education, and the assessment of patient compliance. 
This is a major concern because, while many categories of oral chemotherapies have similar 
levels of toxicity to their infusion counterparts, the levels of safety and monitoring for 
prescription and administration are less rigorous than those for parenteral chemotherapy (Birner, 
2003; Weingart et al., 2007).   
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 Oral chemotherapy may present a particular problem if a patient receiving the therapy is 
admitted to an inpatient setting for an acute episode. In this situation, the admitting provider 
must determine how to continue the oral chemotherapy, frequently without the requisite 
expertise in the medication or the condition in which the oral chemotherapy is prescribed. The 
ASCO/ONS administrative guidelines require that orders for oral chemotherapy be written and 
signed by licensed practitioners who are determined to be qualified by the prescribing institution 
according to its policies, procedures, and/or guidelines (Weingart et al., 2012). Additionally, 
each facility has bylaws which determine which specialties are authorized to prescribe 
chemotherapy. 
 Although many institutions have dedicated oncology units, patients on oral chemotherapy 
may be hospitalized for an unrelated issue and placed on a non-oncology floor. Nurses outside of 
oncology may not be aware that a particular drug is an oral chemotherapy that requires additional 
verifications, safeguards, and special handling, thereby placing themselves and their patients at 
risk. They also may lack the confidence to administer, care for, and educate patients receiving 
oral chemotherapy because of their unfamiliarity with the medications and safe administration 
standards. Specific safety standards for the administration of chemotherapy have been identified 
by ASCO/ONS and require that each institution have a comprehensive educational program to 
include monitoring nursing competency and safe handling and that all patient receive education 
(Jacobsen et al., 2012).  
Theoretical and Conceptual Framework 
 The Iowa Model of Evidence-Based Practice can help nurses and other healthcare 
providers translate evidence-based practice into clinical practice while improving outcomes for 
patients (Brown, 2014). The Iowa Model involves a systematic process that can be described as a 
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progressive series of activities to identify a problem and initiate the need for a change (Titler et 
al., 2001). Currently, the Iowa Model is used by HPH (HPH, 2015; HSCN, 2014) to guide all EB 
projects. The Iowa Model incorporates the following seven steps: 
1. Problem and knowledge focused triggers; 
2. Form a Team; 
3. Assemble Relevant Research and Related Literature; 
4. Critique and Synthesize Research; 
5. Pilot the Evidence-Based Practice Change; 
6. Implement the Evidence-Based Practice Change; 
7. Monitor and Analyze Structure, Process and Outcome Data; 
 Problem-focused triggers. Problem-based triggers that initiated this project included 
prescriptions for oral chemotherapy by non-specialty providers which have led to inappropriate 
continuation in the inpatient setting, administration of oral chemotherapy by untrained staff 
nurses, and a lack of nursing patient education. 
  The current system wide policy and procedure at HPH for the administration of 
chemotherapy was updated in 2015 to ensure system wide alignment with ASCO/ONS standards 
(Blasiak, 2016). The current policy clearly defines who is qualified to prescribe oral 
chemotherapy, gives oncologists the privilege to prescribe chemotherapy, and specifies that non-
oncologists may prescribe chemotherapy only within their specialty and scope of practice. 
Residents are not permitted to prescribe chemotherapy (Straub Medical Center, 2015).  
Although oncologists have the expertise and specialized training to safely prescribe oral 
chemotherapy, they oftentimes are not consulted in the inpatient setting. Oral chemotherapy is 
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prescribed by non-specialty providers who fail to communicate with the original prescribers to 
determine the appropriate course of treatment in the inpatient setting.  
  From June 2016 to December 2016, a total of 332 oral chemotherapy medications were 
ordered across the HPH’s four hospitals (see Figure 1).  Of the 332, 137 of the orders were for 
megestrol acetate. Megestrol is an antineoplastic agent and appetite stimulant that is used for 
weight loss related to certain conditions and there is limited evidence for its use as an appetite 
stimulant outside of these conditions. Currently, megestrol is being used at HPH facilities for 
appetite stimulation outside of labeled indications and for this reason was excluded from the data 
leaving a total of 195 oral chemotherapy orders. Of the remaining 195 orders, only 44, or 
22.56%, were ordered by an appropriate specialty prescriber.  
 Although a system wide prescribing policy is in place, compliance rates varied among the 
four hospital sites. Overall, Kapi`olani Medical Center (KMC) had the best compliance with 36 
of 39 oral chemotherapy orders prescribed by an approved provider, while the remaining three 
sites had notably low compliance. KMC’s high compliance rate was thought to be associated 
with patient population as KMC treats pediatric oncology while the other three sites treat adult 
oncology. Pediatric oncology is typically delivered in the inpatient setting, while adult oncology 
has a heavier outpatient emphasis which places a greater dependence on non-oncologist in the 
inpatient setting.  
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Figure 1. Oral chemotherapy orders prescribed by an appropriate prescriber at Hawai`i Pacific 
Health from June 2016 – December 2016.   
 At SMC, there were a total 92 oral chemotherapy orders (See Appendix A). Of the 92 
only 7% were prescribed by an appropriate specialty provider. Hospitalist prescribed 61% of all 
oral chemotherapy orders (see Figure 2). Additionally, only 5% of orders were administered by a 
chemotherapy competent nurse, and only 9% of patients received education about oral 
chemotherapy at first dose administration.  
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Figure 2. Oral chemotherapy prescriber specialties from June 2016 – December 2016.    
 Knowledge-focused triggers. The ASCO and ONS provide well known published 
standards and guidelines for oral chemotherapy prescription and administration (Neuss et al., 
2013). The current facility policy at SMC align with these standards by indicating who is 
authorized to order oral chemotherapy and the steps required for safe administration (Straub 
Medical Center, 2015). However, gaps in physician knowledge inevitably result in different 
degrees of physician appropriateness for prescribing oral chemotherapy. Additionally, gaps in 
nurse knowledge result in variation in the safe handling, administration and education process. 
 Oncologists have the requisite training and expertise to order oral chemotherapy, yet they 
infrequently prescribe oral chemotherapy in the inpatient setting at SMC. This calls into question 
the experience and knowledge of physicians in other specialties to appropriately apply oral 
chemotherapy medications and to account for their drug interactions and unique side effects.  
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 A recent patient case highlighted this knowledge gap:  patient presented to SMC with 
fever, fatigue, and lab results indicating blood culture positive for gram negative rods. This 
patient was on an oral chemotherapy treatment at home, and after lab review and evaluation, the 
patient was admitted with a diagnosis of sepsis. The admitting physician (hospitalist) continued 
all home medications including an oral chemotherapy drug that is a known neutropenia causing 
agent. After two days, it was discovered that the patient was erroneously continued on the 
medication, which was causing neutropenia and triggering the sepsis. In this example, the 
hospitalist was unaware of the appropriate application of the oral chemotherapy medication and 
there was inadequate communication between the hospitalist, original prescriber, and oncology 
specialty. 
 In another case, a patient on active oral chemotherapy treatment for chronic myeloid 
leukemia had a mechanical fall at home that required an acute hospitalization, unrelated to the 
cancer diagnosis. The admitting physician (hospitalist) continued the patient on the oral 
chemotherapy without a referral to oncology services or communication with the original 
prescriber. The patient was found to have a gangrenous foot ulcer and severe peripheral arterial 
occlusive disease, which the oral chemotherapy medication is known to exacerbate. In this 
situation, the hospitalist lacked the expertise and knowledge that the oral chemotherapy 
medication was making the patient’s peripheral arterial occlusive disease worse. The medication 
was changed immediately when evaluated by an oncology specialist, but not until days after the 
admission. 
Form a Team 
 An interdisciplinary team was established to determine appropriate interventions and 
standardize the process for oral chemotherapy prescription and administration. The team 
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consisted of the Director of Oncology Services, Oncology Physician Assistant (OPA), Oncology 
Practice Counsel (OPC), inpatient pharmacy managers, and nursing managers. 
Assemble Relevant Research & Related Literature 
 A thorough review of the literature began by searching the literature for determining 
strategies that could be used to standardize procedures for oral chemotherapy ordering and 
administration. An electronic search was completed using CINAHL, PubMed, the Cochrane 
Library, and the National Guideline Clearinghouse databases. The majority of applicable results 
were obtained from CINAHL and PubMed. Search terms included “oral chemotherapy”, 
“neoplasms/drug therapy”, “oral adherence”, "administration, oral”, "drug therapy/administration 
and dosage", "antineoplastic protocols", “safety standards”, "medication errors", “administration 
and dosage”, “electronic prescribing”, “computerized provider order entry”, “prescriptions”, 
“patient education”, and “inpatients”. Parameters in both PubMed and CINAHL, such as subject 
headings, Boolean operators, and truncation, were utilized to limit and expand search results as 
needed. Abstracts, full text articles, and bibliographies for related articles were reviewed. 
 The search results produced 108 articles and relevant publications that matched the 
established criteria. Filters eliminated duplicate articles and those that were exclusive to 
parenteral chemotherapy. Inclusion criteria included human subjects over the age of 18, English 
language publications, and inpatient settings. Year limits were set to the past 10 years to ensure 
current research was evaluated, the oldest reviewed study being from 2007. After reviewing 
articles according to the inclusion and exclusion criteria, a total of 25 journal articles and three 
practice guidelines were utilized for this project. 
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Critique & Synthesize Research for Use in Practice 
 A review of the literature revealed a lack of studies examining adherence to ASCO/ONS 
guideline standards for oral chemotherapy in the inpatient setting. Inappropriate prescribing by 
providers without oncology training was identified as a concern, but there was little to no 
evidence to help refine the standard. The majority of the studies reviewed identified gaps in oral 
chemotherapy safety standards, such as variable practices in prescribing oral chemotherapy, 
administering the drugs, and educating patients, but few offered solutions outside of following 
ASCO/ONS standards.  
 The majority of the literature found was Level VI, descriptive studies. Overall, the 
publications were deemed to have fair to good internal validity. No Level I, Level II, or Level III 
research studies were identified, due to the nature of the project topic. Study designs where a 
subject may not receive an intervention, such as randomized controlled trials, are not suitable due 
to ethical concerns that all patients should safely receive medication.  
 The 25 articles were evaluated and ranked in terms of their position on an eight-level 
scale based on the Mosby Research Critique Tool (2004), as presented in Table 1. The three 
practice guidelines were critiqued using the Appraisal of Guidelines for Research & Evaluation 
II (AGREE II) tool, as shown in Table 2. The Mosby Research Critique Tool (2004) has eight 
levels of evidence including a seven-level grading system, with Level I, meta-analyses, being the 
highest level of research. The AGREE II tool is designed to assess the quality of practice 
guidelines and was used to grade performance, usefulness, and areas for improvement. The 
AGREE II tool has a maximum possible score of seven and minimum of one (Brouwers et al., 
2010). 
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Table 1 
Search Results Categorized by Mosby’s Level of Evidence 
Mosby’s Level of Evidence Search Results 
Level I Meta-analysis 0 
Level II Experimental design aka Randomized Controlled Trial (RCT) 0 
Level III Quasi-experimental design 0 
Level IV Case controlled, cohort studies, longitudinal studies 0 
Level V Correlation studies 1 
Level VI 
Descriptive studies including: 
• Surveys 
• Cross sectional design 
• Developmental design 
• Qualitative studies 
16 
Level VII Authority Opinion or expert committee reports 4 
Other: Quality Improvement Project  (QI) 4 
TOTAL:  25 
 
Table 2 
Clinical Practice Guideline AGREE II Score 
Reference  Score 
 
America Society of Health-System Pharmacists, 2014 
Neuss et al., 2013 
Neuss et al., 2017 
 
5 
6 
6 
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 Clinical Practice Guidelines. In order to assist facilities in developing policies and 
procedures ensuring safe administration of chemotherapy, guidelines related to chemotherapy 
preparation, handling, and administration have been released by ONS (Brown et al., 2001; Level 
VII), Infusion Nurses Society (2000; Level VII), and the ASHP (ASHP, 2002; Level VII). In 
2008, the ASCO and the ONS initiated a collaborative project to develop standards for safe 
chemotherapy administration to adult patients with cancer. The scope of the project included 
patient safety with chemotherapy regimens across the treatment course, but did not specifically 
address oral chemotherapy (Jacobson et al., 2009; Level VII). This prompted, another 
ASCO/ONS workgroup to address the challenges surfacing around oral chemotherapy 
treatments. In 2013 the guidelines were updated to specifically address the unique complications 
associated with the use of oral chemotherapy (Neuss et al., 2013; Level VII). The most current 
guidelines were recently updated in 2016 (Neuss et al., 2017; Level VII). In addition, ASHP 
released revised standards in 2014 that included oral chemotherapy (ASHP, 2014; Level VII). 
 While overall adoption is currently lagging for oral chemotherapy, multiple studies have 
concluded that the ASCO/ONS guidelines should be implemented by all facilities, and that oral 
chemotherapy should be subject to the same safety procedures as parenteral chemotherapy (Levy 
et al., 2011, Level VII; Roop & Wu, 2013 - Level VI; Vioral & Kennihan, 2012 - Performance 
Improvement; Weingart et al., 2012 – Level VI). Two studies similarly recognized that the 
administration of oral chemotherapy often lacks not only safeguards similar to those required for 
parenteral chemotherapy, but also standards for ensuring order accuracy, thus giving rise to 
safety concerns (Johnson, Chambers, & Vaida, 2008 – Level VI, Roop & Wu, 2013). In addition, 
Weingart et al. (2012) assessed the overall implementation of the 2009 standards and concluded 
that only four of the 55 National Cancer Institute designated cancer centers were compliant with 
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all 31 safety standards. These studies and the variable implementation of the ASCO/ONS 
chemotherapy safety standards reflect the need for standardized procedures and further 
evaluation of strategies to ensure adherence to standards. 
 A quality improvement project conducted at Gibbs Cancer Center & Research Institution 
assessed standardizing the consenting, ordering, and documenting for oral chemotherapy in 
compliance with ASCO/ONS Chemotherapy Administration standards for inpatient oral 
chemotherapy administration via an algorithm (Hegedus, 2016 – Quality Improvement Project). 
 Oral Chemotherapy Prescribing. Due to the narrow therapeutic index, oral 
chemotherapy agents are often associated with a greater risk of adverse events (AEs) than other 
medications. An even greater incidence of AEs may result when used in combination with other 
medications (Goodin et al., 2011, level VII). In 2010, Weingart et al. analyzed over 500 reports 
of medication errors involving oral chemotherapies and found the majority of incidents resulted 
in, or had the potential for, significant harm. Errors were identified at every stage of the 
medication process (Weingart et al., 2010; Level VI). Two quality improvement projects found 
that by requiring oncology-trained pharmacists to review oral chemotherapy prescriptions prior 
to dispensing prescribing errors for oral chemotherapy were reduced (Battis, Clifford, Huq, 
Pejoro, & Mambourg, 2016 – Quality Improvement Project; Shah et al., 2016 – Quality 
Improvement Project). 
 Oral Chemotherapy Administration. Although no publications compare chemotherapy 
errors that occur with oral administration versus intravenous administration, known issues with 
oral administration include incorrect dosing and limited monitoring. These can lead to 
overdosing, serious toxicity, morbidity, and mortality (Goodin et al., 2011). In one study of 199 
registered nurses working in oncology wards, 26% demonstrated compliance with them during 
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administration even though 73% of them reported knowing the guidelines for safe handling of 
chemotherapy agents. (Kampitsi et al., 2012; Level VI).   
 Oral chemotherapy administration is guided by the ASCO/ONS standards and indicates 
that two independent checks must be completed prior to administration (Neuss et al., 2013). An 
independent double check requires two people to check separately each component of the 
medication order to reduce the risk of bias that occurs when a single person prepares and checks 
a medication (Institute for Safe Medication Practices, 2013). A study that investigated the 
practice of double-checking procedures in chemotherapy administration found that 25% of 
responders reported that one or more serious medication errors had taken place in their unit 
during the past 12 months. A majority of those surveyed believed it could have been prevented 
with a thorough double-check (Schwappach, Pfeiffer, & Taxis, 2016 – Level VI). 
 Computerized Provider Order Entry Systems. Communication from physicians to 
other members of the treatment team takes place primarily through the ordering process, which 
can be complex due to the need for precision with regard to the drug, dose, and scheduling, and 
duration of oral chemotherapy (Meisenberg, Wright, & Brady-Copertino, 2013). Oral 
chemotherapy medications often have narrow therapeutic ranges and complicated dosing 
schedules, which can lead to prescribing errors. Computerized Provider Order Entry (CPOE) 
systems have the potential to prevent oral chemotherapy errors and to improve the quality of care 
for patients receiving oral chemotherapy (Brown et al., 2002 – Level VII; Collins & Elsaid, 2010 
– Level VII). 
 In a study that evaluated the ability of a CPOE system to reduce the probability of oral 
chemotherapy errors during the review and administration process (Collins & Elsaid, 2010), 
CPOE resulted in an approximately 69% reduction in the risk of oral chemotherapy prescribing 
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errors. Prior to the implementation of a CPOE, errors of drug dose and/or schedule comprised 
33% of total prescribing errors. After the CPOE implementation, this type of prescribing error 
was completely eliminated over a 6-month period. This study demonstrates the ability of a CPOE 
system to reduce prescribing errors and potentially eliminate certain error types that can cause 
patient harm (Collins & Elsaid, 2010). 
 A similar study investigated the effects of instituting a CPOE system for chemotherapy 
ordering and administration in an academic teaching institution that admits approximately 1,300 
patients for chemotherapy administration annually (Martin, Kaemingk, Frieze, Hendrie, & 
Payne, 2015 – Level VII). They concluded that the CPOE system for ordering chemotherapy was 
successfully and safely implemented, with staff reporting a decrease in adverse safety events, 
particularly in the areas of prescribing and transcribing. The ASHP Guidelines on Preventing 
Medication Errors with Chemotherapy and Biotherapy (2002) recommend that a CPOE should 
be implemented to further enhance the safety of the chemotherapy ordering process. The CPOE 
system and electronic health record should allow for an electronic check and documentation of 
the independent checks by the pharmacist, nurse, and any others involved in the chemotherapy 
use process. 
 Several studies validated the positive impact CPOE can have on the reduction of oral 
chemotherapy medication errors (ASHP, 2002; Brown et all., 2002; Collins & Elsaid, 2010; 
Gandhi, Tyono, Pasetka, & Trudeau, 2013; Martin, Kaemingk, Frieze, Hendrie, & Payne, 2015; 
Meisenberg, Wright, & Brady-Copertino, 2013). Advantages include providing alerts for missing 
orders, incorrect doses and wrong route, time, and schedule. In addition, CPOE systems provide 
increased communication among healthcare providers and easy access to pertinent patient data 
related to oral chemotherapy ordering and administration (Levy et al., 2011 – Level VII). Several 
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studies identified successful integration strategies to identify safety gaps with input from 
interdisciplinary teams consisting of clinicians, pharmacists, information technology specialists, 
and nurses (Gandhi, Tyono, Pasetka, & Trudeau, 2013; Martin, Kaemingk, Frieze, Hendrie, & 
Payne, 2015). 
Innovation in Practice 
 Standardization of Chemotherapy Prescription and Administration.  Currently, the 
gold standard guiding oral chemotherapy safety is from the ASCO/ONS, which is the most 
highly cited guideline in the literature. These standards require the oral chemotherapy process to 
include prescription by a qualified provider with documented specialized training, preparation by 
a licensed pharmacist with documented chemotherapy preparation education, three independent 
verifications by a second licensed pharmacist, and at least two independent nursing checks prior 
to administration (Neuss et al., 2016). Recommendations for avoiding chemotherapy 
administration errors calls for standardized approaches, development of policies and procedures 
for system improvement, and review of errors by interdisciplinary professional staff (Jacobson et 
al., 2009). The use of an oral chemotherapy prescribing and administration algorithm was shown 
to be an effective approach to standardize the process to align with ASCO/ONS guidelines 
(Hegedus, 2016). The current policy and procedure at SMC was evaluated to expand upon and 
standardize the process for ordering and administering oral chemotherapy, ensuring compliance 
with ASCO/ONS guidelines.   
 Education and Training. Nurses play a vital role in the safe administration of oral 
chemotherapy. In order to ensure alignment with the ASCO/ONS safety standards, it is critical to 
ensure that all staff involved in the oral chemotherapy process have the training necessary to 
ensure safe prescription and administration of oral chemotherapy. The ASCO/ONS updated 
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(2017) safety standards indicate that every healthcare setting must have a policy to document the 
qualifications of clinical staff that order, prepare, and administer chemotherapy. In addition, the 
healthcare setting must use a comprehensive education program providing initial and ongoing 
educational requirements for all staff that prepare and administer chemotherapy. The guideline 
makes clear that patient safety is paramount, and proper training of all staff involved with oral 
chemotherapy must align with current safety standards.    
Summary 
 The purpose of this EB project was to standardize the process for prescription and 
administration oral chemotherapy in compliance with facility policy, ASCO/ONS Chemotherapy 
Administration standards in the inpatient setting at HPH’s SMC.  A comprehensive literature 
review identified key principles and guidelines to follow in order to ensure safe prescription and 
administration of oral chemotherapy. These principles include standardizing the process for 
prescribing and verifying oral chemotherapy, ensuring proper training and education for staff, 
and providing patient education for oral chemotherapy. Based on the evidence reviewed, 
interventions will be incorporated into a practice change to be implemented and evaluated.  
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CHAPTER THREE. METHODS 
Objectives 
 While there is a clearly outlined prescribing policy for oral chemotherapy at SMC, 
patients admitted to the inpatient setting were found to have oral chemotherapy agents prescribed 
(and continued from home) by inappropriate specialty prescribers. Additionally, oral 
chemotherapy was being administered by nurses unfamiliar with the treatment and failing to 
provide patient education. The project used the PICO format to frame its underlying clinical 
question in terms of Population, Intervention, Comparison, and Outcome. Each aspect of the 
clinical question are discussed below. 
 P - Population: Adult patients admitted to a 4th, 5th, and 6th floors at SMC and 
prescribed oral chemotherapy.  
 I - Intervention: Initiation of an oral chemotherapy algorithm addressing prescribing, 
administering, and educating.  
 C - Historical data with current practice.  
 O - Increased compliance with facility policy for prescribing and administering oral 
chemotherapy orders and thereby increased compliance with the ASCO/ONS Chemotherapy 
standards in the inpatient setting at SMC. 
 The primary clinical question for this project is “Will the initiation of an inpatient oral 
chemotherapy prescription and administration algorithm increase the number of oral 
chemotherapy orders that comply with ASCO/ONS guidelines by having orders placed by an 
appropriate specialty prescriber and having the first dose administered by a chemotherapy-
competent nurse?  
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The Practice Change 
 This EB project aimed to standardize the process of oral chemotherapy prescription and 
administration by implementing a system wide process that includes an algorithm to standardize 
the process for prescription and administration of oral chemotherapy (see Appendix B) that 
includes a nursing standardized documentation process for oral chemotherapy. The algorithm for 
prescribing and administering requires the following: 1) a consult is requested for the appropriate 
prescribing specialty, 2) pharmacy reviews and releases oral chemotherapy orders only when the 
order is written by an oncologist or approved specialty prescriber, 3) the first dose of every oral 
chemotherapy order is administered by a chemotherapy-competent nurse who provides essential 
staff and patient teaching that is documented via SMART phrase in the electronic medical record 
(EMR) algorithm (see Appendix C).  
 Components such as education for physicians, pharmacists, and nurses were performed in 
small groups to clarify the existing prescribing and administration oral chemotherapy policy, as 
well as the standardization of the prescription and administration process by integrating the 
algorithm and SMART phrases. The algorithm was designed to incorporate EB literature 
recommendations and SMC and ASCO/ONS guidelines. The algorithm’s development included 
contributions from key stakeholders including the Director of Oncology Services, OPC, OPA, 
inpatient nurse managers, and pharmacy leadership. 
Characteristics of the Innovation 
 In order to increase adoption of the proposed practice change, five perceived attributes of 
the innovation were examined. These attributes included relative advantage, compatibility, 
complexity, trialability, and observability (Rogers, 2003). The following section identifies 
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features of the practice changes proposed by the current project that correspond to the five 
perceived attributes of innovation.   
 Relative advantage. Relative advantage, as explained by Rogers (2003), is the degree to 
which an idea or innovation is superior to the existing idea. The foremost advantage of this 
project addresses patient and staff safety. Unlike parenteral chemotherapy, oral chemotherapy 
medications were not ordered or administered via a standardized process, leaving gaps in patient 
and staff safety. With successful implementation, this project intends to decrease the number of 
inappropriate specialty prescribers ordering oral chemotherapy. It also aims to increase staff and 
patient safety by ensuring that nurses were aware of safety precautions necessary for handling 
hazardous drugs and the unique side effect profile associated with the medications. Additionally, 
it ensured that oral chemotherapy education for patients is completed and documented. 
 Compatibility. Rogers (2003) describes compatibility as the degree to which an idea or 
innovation is in line with the present values, experiences, and needs of likely adopters. The HPH 
organization recently addressed the lack of standardization for verification and administration of 
parenteral chemotherapy and successfully implemented a system wide policy that is currently in 
use (Blasiak, 2016). This policy included guidance on oral chemotherapy; however, project 
baseline data indicated a lack of compliance at three of the four hospitals triggering this project. 
This project was highly compatible with the current parenteral chemotherapy process and 
utilized similar procedures to develop interventions that have been proven successful and that 
complement the existing policy. 
 Complexity. Complexity is described by Rogers (2003) as the degree to which an idea or 
innovation is understood as difficult to comprehend and use. This project would implement an 
algorithm to decrease complexity and create a clear and defined process for ordering and 
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administering oral chemotherapy. The algorithm will provide a step-by-step, easy to follow guide 
that observes system policy and ASCO/ONS guidelines. 
 Trialability. Every inpatient oral chemotherapy order was an opportunity to test the new 
standardized process. With each order, evaluation of individual parts could be assessed and 
modified as needed. Furthermore, the process would only be piloted at SMC before HPH system 
wide implementation, which allowed for further reevaluation as necessary.  
 Observability. Observability is defined by Rogers (2003) as the degree to which the 
results of an innovation are observable to others. Results can be observed by approved specialty 
prescribers and pharmacy staff through an increase in communication for verification of oral 
chemotherapy orders and pharmacy. In addition, nursing staff will see an increase in patient 
education in oral chemotherapy orders administered by a chemotherapy-competent nurse for the 
initial dose. Although not directly visible to leadership, review of data will show increased use of 
SMART phrases that standardize the process of oral chemotherapy prescription and 
administration and provide a way to track the data. 
Sampling Plan 
Setting 
 HPH is a not-for-profit health care system of medical centers, clinics, physicians and 
other care providers throughout the state of Hawai`i. The health care system includes four major 
hospitals: Straub, Kapi`olani, Pali Momi, and Wilcox. (HPH, 2015). The new standardized 
process aimed for system wide implementation, but initial implementation took place at SMC 
due to its high volume of oral chemotherapy orders and low compliance with chemotherapy 
prescribing and administration policy. SMC is a fully integrated medical center with 159-beds 
located in Honolulu, Hawai`i and offers more than 32 medical specialties, including oncology 
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(HPH, 2015). SMC is currently accredited by the Commission on Cancer as a Community 
Cancer Care Center and passed reaccreditation requirements in 2015. In addition, SMC is fully 
accredited by the Joint Commission on the Accreditation of Healthcare Organizations.  
 At SMC, the 6th floor serves as the oncology unit, but many patients on oral 
chemotherapy regimens are admitted to other non-oncology units for acute issues. Baseline data, 
from June 2016 – December 2016, indicated that the 4th, and 5th floors have the highest volume 
of oral chemotherapy orders and served as the setting for the interventions along with the 6th 
floor oncology unit.  
 Oral chemotherapy sample. The sample for the project included all oral chemotherapy 
orders prescribed to inpatients on the 4th, 5th, and 6th, floors at SMC from October 2017 to 
December 2017. Inclusion criteria included all oral chemotherapy orders with the exception of 
megestrol. All intravenous, subcutaneous, or intermuscular chemotherapy was excluded from the 
project. 
 Recruitment and marketing plan. Frequent and effective communication is essential 
for successful implementation of a change in practice. There are many channels of 
communication that can be used to transmit the information within a social system. Rogers 
(2003) identifies two methods in which communication can be applied: mass media and 
interpersonal channels.  
 Mass media. Rogers (2003) explains that mass media can enable rapid communication to 
a large audience, create knowledge, spread information, and change weakly held attitudes. The 
mass media channels used for this project included e-mails and the SMC’s hospital intranet 
communication. E-mail was utilized to initiate mass communication and provide information 
about the standardized oral chemotherapy prescription and administration process along with the 
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algorithm. Although e-mail generates the ability to reach a large audience, it does not itself 
provide the level of communication necessary for implementation of the project and was 
combined with interpersonal channels. 
 Interpersonal channels. Interpersonal channels of communication can be more effective 
than mass media in convincing individuals to change practices (Rogers, 2003). Due to possible 
resistance to a change of process for the prescription and administration of oral chemotherapy, 
face-to-face meetings were arranged to provide information about the new process and 
algorithm. Monthly face-to-face meetings were conducted with key stakeholders which include 
the Oncology Practice Council, nurse managers of the inpatient floors, and inpatient pharmacy.  
 Opinion leaders are effective in changing behaviors and facilitating the diffusion of 
innovation. These individuals are viewed as a respected source of influence, considered by 
colleagues as technically competent, and trusted to judge the fit between the innovation and the 
local situation (Titler, 2001). The opinion leader, Director of Oncology Service Line, was 
involved in developing the communication strategies to fit the culture of SMC. A series of face-
to-face educational in-services were presented to key stakeholders, oral chemotherapy 
prescribers, clinical pharmacist, and all inpatient nursing managers.  
Data Collection 
Data Management Plan 
 A data management plan establishes how project data would be collected, managed, and 
analyzed while ensuring creditability. The following subsection will describe the data sources, 
collection procedures and plan for data analysis. 
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 Data sources. Currently, the only data source for tracking oral chemotherapy orders is 
electronic drug orders from the pharmacy. Data elements that will would collected from the 
pharmacy are listed in Table 3.  
Table 3 
Data Source 
Data Source  Elements 
All oral 
chemotherapy orders 
pulled from 
pharmacy  
1. Date ordered  
2. Medication  
3. Ordering provider and specialty  
4. Nursing Unit 
5. First dose administration  
6. Verification user  
 
SMART phrase  1. Nursing patient and staff teaching during first dose administration from 
chemotherapy-competent nurse 
 
 Data collection procedures. Data was collected monthly via the EMR system by a key 
stakeholder from the pharmacy and electronically transmitted in a Microsoft Excel file for 
evaluation. The data was aggregated without identifiers and securely exchanged to ensure 
confidentiality. Both baseline and implementation data were collected using the same method. At 
baseline, oral chemotherapy orders were abstracted once a month for 7 months (June 2016- 
December 2016) and post implementation records were abstracted once for three month 
beginning October 2017, with final data from December 2017. 
 Data analysis. Data was analyzed on a monthly basis and included all oral chemotherapy 
orders to determine if there was a change from the baseline. Specifically, all oral chemotherapy 
orders were analyzed to determine if 1) the appropriate specialty prescribed the oral 
chemotherapy order, 2) a chemotherapy-competent nurse administered the first does of oral 
chemotherapy and provided education to staff and patients documenting via SMART phrase.  
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Evaluation Plan  
 The evaluation design is an impact evaluation that uses an observational T1-T2 test to 
determine the impact of a new algorithm on the number of oral chemotherapy orders that comply 
with facility policy and ASCO/ONS guidelines. The evaluation measures the impact of the 
algorithm on prescriber specialty, first dose administration by a chemotherapy-competent nurse, 
and patient education. T1 will include baseline data from June 2016 – December 2016 and T2 
will be January 2017 – December 2017. The following section will describe and operational 
definitions necessary for this analysis.   
Additional Operational Definitions 
1. Approved Oral Chemotherapy Prescriber: Licensed independent practitioner as 
determined by state law and the facility who prescribes chemotherapy and/or 
biotherapy (ONS, 2014).  
2.  Chemotherapy-competent Nurse: A nurse who has been trained to administer 
chemotherapy with evidence of completing the ONS chemotherapy and biotherapy 
certificate course, chemotherapy skills course, initial on-unit competency, and 
ongoing education as evidence by annual competencies. Documents first dose 
administration of oral chemotherapy patient and staff education with SMART phrase 
 3.  SMART phrase: Standardized documenting method in the EMR.    
Timeframe 
 Development of a project timeline is an essential part of coordinating an EB practice 
change. Initial stages of the project began in June 2016 and included team development and 
discussions with facility and site leadership. Implementation of the interventions began in 
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October 2017. Data collection for the implementation took place between October and December 
2017 (see Appendix F). 
Resources 
 Although program funding is often one of the most vital resources for the successful 
implementation of a program, this project did not require a financial outlay. The resources 
utilized were both time and human. The project required time from the Director of Oncology 
Services, OPA, nursing managers, and pharmacy staff to give input about developing and 
implementing the new process and to provide education and training on the new process. 
Additionally, time was necessary from the key stakeholders during the process of modifying the 
process and interpreting the results.  
Human Subjects Considerations 
 The guiding principles of autonomy, non-malfeasance, beneficence, and justice were 
upheld when designing this quality improvement project. All data collected was in aggregate 
form, without identifiable information related to personnel. Vulnerable populations were not 
included; participants were not randomized; and all patients received the same standard of care. 
The project did not involve the administration of medical procedures; therefore, informed 
consent was unnecessary and was not collected. The principles of non-malfeasance and 
beneficence were upheld as the proposed interventions for standardizing the oral chemotherapy 
prescription and administration process included no additional patient and staff risk, outside of 
standard practice. The overarching goal of this project was to improve upon patient and staff 
safety, achieve the best possible patient outcomes, and ensure the rights, welfare, and greater 
benefit of all patients and staff who participated. 
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Limitations 
 Many limitations were identified despite efforts to minimize them. Time was a 
considerable factor as the project was only implemented and evaluated over a period of 3 
months. Design limitations included variability in the practice setting and inability to control for 
variables and create constant conditions. There was a lack of high-level evidence guiding 
implementation selection, and the algorithm and chart audits utilized non-validated methods. 
Additionally, a small sample size limited the generalizability and applicability of the project. 
Summary 
  This chapter presented a description of the practice change, sampling plan, data 
management plan, resources, and human subject considerations. The purpose of this project was 
to standardize the process for prescribing and administering oral chemotherapy that complies 
with facility policy and the ASCO/ONS Chemotherapy Administration standards in the inpatient 
setting at at SMC.  
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CHAPTER FOUR. RESULTS 
Description of the Sample 
Oral Chemotherapy Doses  
 The sample for the project was oral chemotherapy orders prescribed to inpatients on the 
3rd, 4th, and 5th floors from October 2017 to December 2017. The sample size was 11 doses and 
the average was four per month (see Figure 3).  At baseline from June 2016 to December 2016, 
the average number of doses was 13 per month. During the algorithm implementation from 
October 2017 to December 2017, the average monthly volume trended down and decreased 70 
percent from baseline.  
 
Figure 3. Oral Chemotherapy Doses per Month 
Trend Analysis  
 The T1 and T2 impact evaluation measured the percentage change for the following 
measures at baseline and post implementation: (1) percentage of oral chemotherapy orders 
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prescribed by an appropriate specialty, (2) percentage of oral chemotherapy orders administered 
by a chemotherapy-competent nurse, and (3) percentage of patients who received oral 
chemotherapy education at first dose administration (see Table 4).  
Table 4 
T1-T2 Impact Evaluation: General Findings 
 
% Oral chemo 
prescribed by 
appropriate specialty 
% Oral chemo 
administered by 
Chemo-competent RN 
% Patients 
received oral 
chemo education 
Baseline (T1) 7% 5% 9% 
Comparison (T2) 64% 64% 55% 
Change Δ +57% +59% +46% 
 
Oral Chemotherapy Prescriber 
 Based on feedback, the prescribing component of the algorithm was modified and 
delayed implementation (see Appendix G). Pharmacy staff recommended a prescribing carve out 
for hormonal agents since they are not categorized as hazardous drugs per the National Institute 
for Occupational Safety and Health (NIOSH). This modification categorized non-specialty 
prescribers as appropriate prescribers when ordering antiandrogens, aromatase inhibitors, and 
selective estrogen receptor modulators that meet specific criteria and must be screened by a 
pharmacist (see Appendix H). Pharmacy review and documentation of the carve out process 
during implementation was captured and is presented in Figure 4. After implementation of the 
updated algorithm with the hormonal carve out, 64% of orders were prescribed by an appropriate 
specialty prescriber compared to 7% at baseline (see Figure 5).  
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Figure 4. Pharmacy Progress Note for Oral Chemotherapy Review 
 
Figure 5. Percent of Oral Chemotherapy Prescribed by Appropriate Specialty with updated 
algorithm 
Oral Chemotherapy Administration  
 The administration process did not undergo any changes during the implementation 
period. At baseline, 5% of oral chemotherapy orders were administered by a chemotherapy-
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competent nurse. After implementation, 64% were administered by a chemotherapy competent 
nurse (see Figure 6). 
 
Figure 6. Percent of Oral Chemotherapy Orders Administered by a Chemotherapy-Competent 
Nurse 
Patient Education  
 The patient education piece of the process was not modified also remained unchanged 
during the implementation period. At baseline, patient education was provided to 9% of patients. 
Post implementation, 55% of patients received education (see Figure 7). Documentation was 
reviewed related to three primary sources: the SMART phrase, the DAR (Data/Action/Response 
Note), and the Plan of Care. An example of the SMART phrase captured during chart review for 
documentation appears in Figure 8. 
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Figure 7. Percent of Oral Chemotherapy Orders and Patient Education 
Figure 8. Oral Chemotherapy Patient Education SMART Phrase Documentation   
Hospital Event Reports 
 At baseline there were no event reports related to oral chemotherapy. Integrating a 
chemotherapy-competent nurse into first dose administration led to two separate event reports. In 
one of the reports, an oral chemotherapy medication was ordered by a prescriber, dispensed by a 
pharmacist, but held at the bedside when the chemotherapy-competent nurse reviewed the order 
with the patient prior to administration and discovered that the patient was no longer on that 
medication. In the second event report, a chemotherapy-competent nurse discovered that a 
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patient required an oral chemotherapy medication, was able to verify with prescribing doctor 
from Louisiana, and ordered the medication. 
Evolution of Project  
 Since this project served as a form of quality improvement, continuing assessment and 
modifications were anticipated throughout process. The project was evaluated and modified 
before and during the implementation phase based on feedback from hospitalists, pharmacy staff, 
and nursing mangers. The original implementation period was expected to begin in August 2017, 
but was delayed due to modifications to the process. 
  In the original algorithm (see Appendix B), before hospitalists prescribed an oral 
chemotherapy they would consult the original prescriber of the medication or a SMC specialty 
provider. Feedback from the hospitalist indicated the process for consulting a specialist is done 
by telephone and not electronically, thereby creating additional work. The feedback suggestion 
was that pharmacy should be involved in the process. Pharmacy was consulted and agreed to 
modify the process and review all oral chemotherapy orders. The algorithm was modified by 
adding the following steps: 
o Hospitalist will enter a pharmacist consult to evaluate oral cytotoxic medication – but 
will not enter medication order. 
o If consult received in the eve/night, pharmacist will leave for follow up the next day.  
o 6th floor pharmacist will follow up with provider and document brief note. 
o If specialist is a provider outside of HPH, pharmacist will discuss with outside provider 
and document a note and discuss with hospitalist. 
o If hospitalist does not feel comfortable with ordering, the hospitalist will be directed to 
contact outside specialist to discuss specific clinical situation. 
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o If oncology patient, OPA will be consulted to provide assessment /documentation of plan.  
o Once order is entered, 6th floor charge will be notified to provide 1st dose administration, 
patient education, and documentation. 
 The updated algorithm was presented to the hospitalist group. While they were receptive 
to the new updated process, they asked for the following except for the following change:  
o If the specialist is a provider outside of HPH, the pharmacist will discuss with the outside 
provider, document note, and order under the hospitalist if therapy continues. 
The algorithm was further modified to eliminate this component. Instead the pharmacist would 
evaluate the medication but the specialty prescriber would be responsible for ordering the 
medication, not the hospitalist (see Appendix I). This version on the algorithm was implemented 
on October 1, 2017.  
 During the implementation, pharmacy suggested a prescribing carve out for hormonal 
agents (antiandrogens, aromatase inhibitors, selective estrogen receptor modulators) since they 
do not fall under the NIOSH 2016 Hazardous Drug List. The exception allows non-specialty 
prescribers to order selected hormonal drugs that meet criteria and are screened by a pharmacist 
to meet criteria (see Appendix G). The algorithm was modified a final time to reflect the new 
process (see Appendix H). There were no changes to the administration or education parts of the 
algorithm.  
 Near the end of the implementation period, the pharmacy captured three patient examples 
that highlighted some challenges and opportunities for additional modifications in (see Table 5).  
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Table 5 
Patient Examples of Challenges for Oral Chemotherapy Prescription 
Example  Challenge  
Patient 1 Pt was admitted for surgery for colon cancer and takes 
mercaptopurine for crohns prescribed by Straub GI. 
Medication reordered on admission by surgery resident: 
Day 1: Pharmacist does not verify. Order left in queue.  
Day 2:  Patients GI not working.  Called on call GI.  Did not 
want to order, deferred to Oncology.  Patient has not seen 
outside oncologist yet and medication is not for oncology 
indication.  Oncology declines to order.  Order left in queue to 
attempt follow-up with patient’s own GI next day. 
Day 3: Patients GI not working.  Called GI again.  Staff in 
clinic updated on situation. They follow-up with Dr. XX.  Per 
Dr. XX, ok to hold medication for the next few days, resume 
upon discharge or when patient’s GI is back in office (in 2 
more days).  Patient upset because the patient brought in own 
supply and wants to take it. 
 
Patient 2 Pt admitted with respiratory issues.  Takes Ofev (nintedanib) 
for pulmonary fibrosis order by Straub Pulmonary:  
Day 1: Pharmacist does not verify.  Order left in queue.  
Admitting doctors note said he already consulted doctor 1. 
Tried to page doctor 1, page operator would not page doctor 1 
because it’s the weekend and doctor 2 is on call.  Sent in basket 
to doctor 1 and doctor 2.  No order entered.  
Day 2: Pharmacist discussed with Dr. YY, verified order in 
queue from attending and made a med note.  Concerns that 
missed doses may have caused harm.  Confusion regarding if 
this medication would fall under our protocol. 
 
Patient 3 Patient admitted with polycythemia vera. Takes hydrea ordered 
by Straub Oncologist. 
Day 1: Pharmacist does not verify.  Order left in queue. 
Day 2: Pharmacist speaks with Oncology PA.  In baskets 
patient’s oncologist to re-enter order.  Oncology PA will also 
ask him to order.  No order entered. 
Day 3: No order entered.  Patient discharged. 
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Expected Outcomes versus Actual Outcomes  
 Table 6 outlines the expected versus actual outcomes in relation to the key aspects of the 
project. A description of facilitators and barriers will also be discussed.  
Table 6 
Expected Outcomes versus Actual Outcomes 
 Expected outcomes Actual outcomes 
Timeline  • Implementation period Jul 
2017 – Dec 2017 (6 months)  
• Implementation period Oct 2017 – Dec 
2017 (3 months)  
Oral 
Chemotherapy 
Orders  
• Monthly volume of oral 
chemotherapy would 
decrease from an average of 
13 doses   
• 70% decrease in oral chemotherapy 
orders, average 4 doses per month  
• Hospitalists now questioning 
appropriateness of medication and not 
unnecessarily continuing in acute 
setting 
Prescription   
• Increase in oral 
chemotherapy orders by 
appropriate specialty  
• Integration of crave out for hormonal 
medications  
• 64% of orders prescribed by 
appropriate specialty   
• Increase in communication between 
prescriber and appropriate specialist   
Administration  
• Increase in number of first 
doses administered by a 
chemotherapy-competent 
nurse  
• 64% of first doses were administered 
by chemotherapy-competent nurse  
• Four orders on 6th floor oncology unit  
• Three orders on non-oncology unit  
Education 
• Increase in number of 
patient who receive 
education by at first doses 
administration   
• SMART phase built October 
2017 
• 55% of patients received education at 
the first dose administration  
• SMART phase built December 2017 
• SMART phase for standardize 
documentation used for one order  
• DAR documentation used for five 
orders 
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Facilitators  
 There were several facilitators identified for this project. Due to the collaboration 
necessary to address oral chemotherapy prescription and administration, an interdisciplinary 
approach was required for successful implementation. The Director of Oncology Services served 
as the key facilitator of the project objectives and ensured support from hospitalists, pharmacy, 
nursing, and oncology services.  Pharmacy staff and nursing management were additional key 
facilitators of the project as they were at the center of the prescription and administration process 
and continually helped to modify and improve the process. 
Barriers  
 A major barrier for implementation of this project was time as the implementation period 
was reduced from six to three months. It took additional time to modify the prescription process 
to ensure it was not impeding workflow for hospitalists, pharmacists, and nurses. The SMART 
phase was not available in the EMR until December 2017. More time might have allowed for a 
demonstration of increased use. Also, many of the initial interventions suggested for this project 
included interventions within the EMR, such as pop ups to alert that the medication is an oral 
chemotherapy, but limited time prevented extensive adjustments to the EMR system. The 
process was still evolving as of March 2018 and is expected to continue to evolve and improve. 
  Other barriers associated with data collection played a role. For example, the initial oral 
chemotherapy education data did not capture education that was within the DAR note, but 
individual chart review was able to confirm that education was given to patients. Another barrier 
was a lack of a method for tracking pharmacy interventions in the oral chemotherapy process. 
Anecdotal findings revealed interventions by pharmacists that resulted in oral chemotherapy 
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medications being held due to the pharmacy review. Currently, there is no way to quantify this in 
the results; however, moving forward pharmacy will be working on a tracking method.  
Summary 
 This chapter described the results of the practice change, a comparison of expected versus 
actual outcomes, and facilitators and barriers that affected the project. Overall, the project 
objectives were met with an increase in standardizing the process for prescribing and 
administering oral chemotherapy that complies with facility policy and ASCO/ONS 
chemotherapy guideline standards. 
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CHAPTER 5. DISCUSSION 
Interpretation of Findings  
Oral Chemotherapy Prescription 
 Volume. The average monthly volume of oral chemotherapy orders significantly 
decreased during the implementation phase even though the overall volume for oncology 
services remained consistent. At baseline, the average number of doses was 13 per month. After 
implementation, the average decreased to four per month. The decline is thought to be attributed 
to educating the hospitalist staff about the oral chemotherapy prescribing policy and encouraging 
them to critically evaluate and question whether a medication should be continued in the acute 
inpatient setting. The data shows a significant decrease in orders beginning in October 2017. 
This might be attributed to the influence of two presentations about the project given to the 
hospitalist staff in September 2017 along with implementation of the algorithm. It was thought 
that an increase in communication between the original prescriber and hospitalist also 
contributed to the decline. Figure 9 captures EMR documentation communication with the 
original prescriber in which the urologist was contacted and verified the continuation in the 
inpatient setting. At baseline, during medication reconciliation, oral chemotherapy was being 
continued without questioning and often times despite the need to discontinue. 
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Figure 9. Oral Chemotherapy BPA alert 
 Pharmacy. Pharmacy collaboration was essential to the project and contributed to the 
positive outcomes of the process. The integration of the hormonal carve out into the algorithm 
had a positive impact and increased the percent of appropriate prescribing. Going forward, the 
hormonal carve out will continue as part of the process change.  
 Pharmacy leadership expressed the value of the project and its impact on improving 
pharmacy’s internal process for screening oral chemotherapy orders, which was updated after the 
completion of the data collection (see Appendix J). In January 2018, pharmacy requested a Best 
Practice Advisory (BPA) alert in the EMR for order verification to prompt the pharmacist to 
review all oral chemotherapy orders (see Figure 10). On February 1, 2018 the BPA alert and 
process was implemented (see Appendix K).  
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Figure 10. Oral Chemotherapy BPA alert 
 The three case study examples provided by pharmacy in Table 5 offered an opportunity 
to improve the process. Patients one and two were both prescribed oral chemotherapy for a non-
oncology indication and would follow the process to have the appropriate specialty prescriber 
order the medication, in these cases gastrointestinal and pulmonary. These two examples 
highlight the need to educate the non-oncology specialty prescribers and ensure they are aware of 
the process change and expectations for ordering medications, that non-specialty prescribers are 
unapproved to order. 
 The project continues to develop even after the completion of the implementation period. 
In January 2018, it was suggested that all oral chemotherapy medications be delivered to the 6th 
West oncology floor. A yellow medication bin in the chemotherapy drawer would be labeled 
“ORAL CHEMO” to alert the nurses that there is a first dose to be administered on another floor 
to help to prevent the other floors from administering without a chemotherapy-competent nurse, 
the proper verification, and education. In response, pharmacy labeled all oral chemotherapy 
capsules and tablets with yellow stickers but the challenge will be to maintain this process since 
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hundreds of drugs are affected. Pharmacy will also label the outer bag to always say “hazardous” 
to match the label on the medication administration record (MAR). Additionally, pharmacy is 
trying to implement a first dose sticker and paper notification for oral chemotherapy. Nursing 
leadership will need to continue educating nurses on all units to review the MAR, look for 
stickers, and continue following the algorithm by contacting the the 6th floor nursing unit for first 
dose. 
Oral Chemotherapy Administration 
 The project increased the number of oral chemotherapy orders administered by a 
chemotherapy-competent nurse and improved compliance with safety measures for patients 
receiving oral chemotherapy. There were two event reports directly related to administration that 
were reported by chemotherapy-competent nurses at the first dose administration. This 
demonstrates the awareness and critical thinking involved when adding a nurse trained in 
chemotherapy to the administration process. Integrating chemotherapy-competent nurses into the 
process not only improves safety but impacts nursing knowledge for non-oncology nurses. 
Chemotherapy-competent nurses provided nursing education on safe handling, exposure 
precautions, potential side effects, drug interactions, and adherence to policies and protocols. 
Oral Chemotherapy Education  
 Patient education by nurses is required when administering oral chemotherapy. During 
project implementation, education was increasingly performed by nursing staff but was 
documented in a variety of ways. There were instances where oral chemotherapy education was 
not found on the Plan of Care but was identified during chart review in the DAR note. The 
SMART phase was expected to be available in October 2017 but was not built in the EMR until 
December so it was only utilized once. More education is needed to ensure nursing staff is aware 
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of the SMART phase tool, especially on the non-oncology units, and reinforcing its use and the 
importance of standardizing documentation.  
Implications and Recommendations for Based on DNP Essentials  
 The eight DNP essentials are foundational skills that doctoral graduate nurses are 
expected to possess according to the American Association of Colleges of Nursing (2006).  
Table 7 outlines the foundational competencies in the development, implementation, and 
evaluation of the EB project. 
Table 7 
Implications and Recommendations Based on the DNP Essentials 
DNP Essentials Implications & Recommendations  
ESSENTAL I: 
 
Scientific Underpinnings for 
Practice 
 
1. Evidence based algorithm to standardize the oral 
chemotherapy prescription and administration process in 
the inpatient setting.  
2. Iowa model of evidence based practice utilized as process 
framework. 
 
ESSENTIAL II: 
 
Organizational & Systems 
Leadership for QI & 
Economics 
 
1. Collaboration with leadership to create and sustain 
changes at the organizational levels. 
1. 2. Expansion of standardize the oral chemotherapy 
process from site to system wide. 
ESSENTIAL III:  
 
Evidence-Based 
Practice/Translation Science 
 
1. Critically evaluated existing literature to determine and 
implement the best evidence for practice. 
2. Designed and implement oral chemotherapy processes 
and evaluated outcomes of practice 
 
ESSENTIAL IV: 
 
Information 
Systems/Technology 
 
1. Literature review utilizing electronic databases.   
2. SMART phase created for standardized nursing 
documentation 
3. Requesting to build in EMR for order verification for 
pharmacy 
 
ESSENTIAL V: 
 
Health Care Policy & Ethics 
1. Analyzed HPH’s policy process for future review and 
update of chemotherapy policy.  
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ESSENTIAL VI: 
 
Inter-professional  
Collaboration 
1. Communication between nursing, pharmacy, physicians, 
and leadership related to oral chemotherapy prescription 
and administration in the inpatient setting. 
2. Collaboration with pharmacy, nursing, and physicians to 
modify algorithm process.    
 
ESSENTIAL VII: 
 
Prevention and Population 
Health 
 
1. Standardized oral chemotherapy process addressed risk 
reduction of inappropriate medication continuation in the 
inpatient setting 
2. Staff risk reduction addressed for improper handling of 
hazardous medication.  
 
ESSENTIAL VIII: 
 
Advanced Nursing Practice 
& Education 
1. Designed, implemented, and evaluated standardized 
process for oral chemotherapy prescription and 
administration.  
 
 
Plans for Dissemination and Sustainment 
 Dissemination of the project results will be shared though multiple channels. First, the 
project will be defended at the University of Hawai`i at Mānoa. Organizational dissemination of 
results will be shared onsite with project stakeholders involved in the process. The results of the 
project will be presented to the HPH Cancer Committee as a quality improvement project. If the 
project receives approval by the Cancer Committee, it be implemented throughout the HPH 
system providing ongoing sustainment. Additionally, a manuscript will be prepared for 
submission to a peer-reviewed nursing journal as the process has potential for adoption in other 
facilities.  
Summary 
 In conclusion, this EB project to standardize oral chemotherapy prescription and 
administration in the inpatient setting improved the overall process. Results revealed project 
objectives met with an increase in prescribing and administering oral chemotherapy that 
complies with facility policy, and ASCO/ONS Chemotherapy. Implementing the algorithm 
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decreased the volume of orders, increased the number prescribed by an appropriate specialty, 
increased the number administered by a chemotherapy-competent nurse, and increased the 
number of patients that received education. The process continues to improve and evolve with 
input from key stakeholders. The project will be presented to the HPH Cancer Committee for 
consideration of system wide adoption to deliver quality care to patients.  
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Appendix A 
Inpatient Oral Antineoplastic Medications Prescribed June 2016- December 2016 
 
 
 
 
Anastrozole	(ARIMIDEX)20%
Bicalutamide	(CASODEX)18%
Hydroxyurea	(HYDREA)17%
Letrozole	(FEMARA)12%
Methotrexate10%
Tamoxifen	(NOLVADEX)8%
Exemestane	(AROMASIN)4%
Abiraterone	Acetate3%
Nilotinib	3%
Leucovorin	2%Enzalutamide1%
Erlotinib	(TARCEVA)1% Enzalutamide1%
Oral	Chemotherapy	Drugs	Ordered	at	SMC	
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Appendix B 
Inpatient Oral Antineoplastic Prescribing and Administering Algorithm (Version 1) 
 
 
Inpatient Oral Antineoplastic 
Ordered 
Is it a          
Cancer Patient? Yes
Is there                 
an inpatient  
Oncology PA 
consult? 
Yes
No
Communication 
with original 
prescriber initated 
and documented 
Original prescriber 
OR Approved 
HPH prescriber to 
order  
MD/Pharmacy/Nursing 
to request consult 
Oral 
Chemotherapy 
Administraion 3rd, 
4th, 5th floor 
RN to contact 
6th Floor 
Nursing Charge 
RN 352- 7801 
(cell)
Charge RN to 
review orders 
Chemo Competent RN to administer 1st dose.              
Chemo RN Performs:                                                           
1.Patient education 2. Ensure off unit education       
Chemo RN Documentation:                                                  
1. SMART Phrase documentation in EMR:           
-Verification                                                                     
-Pt education & Understanding                                                               
-Staffed & Hand off 
No
Original  
prescriber 
contacted? 
Yes
No
MD/Pharmacy to 
contact original 
prescriber 
SMART Phrase 
documention in 
EMR
SMART          
Phrase 
documention in 
EMR?
Pharmacy to 
dispense oral 
chemotherpy 
Yes
Pharmacy to 
dispense oral 
chemotherpy 
Original Prescriber 
OR Approved 
HPH prescriber to 
order  
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Appendix C 
Nursing SMART Phrase Documentation for Oral Chemotherapy  
Patient prescribed ___(Oral Chemo)____. Time-out, independent double check procedure 
performed by ____(Autofill with RN name)_____ & ______(floor RN)_____ prior to 
administration. Patient educated on potential side effects such as fatigue, skin reaction, nausea, 
vomiting, flu-like symptoms, fever, and hair loss. Educated on symptoms of adverse reactions 
and when to seek immediate medical attention. Patient verbalized understanding. Available 
Nursing staff educated on safe handling, exposure precautions, potential side effects and drug 
interactions. Medication administered and oral chemotherapy education to be passed on to 
subsequent RNs caring for the patient. 
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Appendix D 
Hawai`i Pacific Health Chemotherapy Prescribing and Administration Policy  
A. Prescribing: 
 1. Oncologist will have the knowledge which has been provided through the documented 
 training program, that includes but is not limited to the following: chemotherapy 
 pharmacokinetics; the side effect profiles of chemotherapeutics agents and appropriate 
 treatments; appropriate routes of administration; use of personal protective equipment; 
 appropriate disposal. In addition, oncologist who prescribe chemotherapy shall have been 
 trained as part of an accredited fellowship or equivalent in the specific skills required to 
 administer chemotherapy. Those so credentialed will be listed.  
 2. Non-Oncologist will be allowed to prescribe anti-neoplastic agents only within their 
specialty and scope of practice (HPH, 2015).  
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Appendix E 
American Society of Clinical Oncology and the Oncology Nursing Society Chemotherapy 
Administration Standards (Selected Excerpts) 
ASCO/ONS guidelines section 1.1. The health care setting has a policy to document the 
qualifications of clinical staff who order, prepare, and administer chemotherapy and documents: 
 1. Description of initial education (1.1.1).  
 2. Description of at least annual ongoing continuing education requirements (1.1.2).  
 3. Description of credentialing process and how credentialing is documented (1.1.3).  
 4. The health care setting uses a comprehensive education for initial and ongoing 
 education requirements for all staff who prepare and administer chemotherapy (1.1.4).  
The ASCO/ONS guidelines section 2.3. Patients are provided with verbal and written or 
electronic information as part of an education process before the first administration of treatment 
of each treatment plan. The content of this educational material will be documented. Educational 
information includes the following at a minimum:  
 1. Patient diagnosis (2.3.1).  
 2. Treatment objectives (2.3.2). 
 3. Planned duration of treatment and schedule (2.3.3).  
 4. Potential long-term and short term side effects of therapy (2.3.4).  
 5. Symptoms or adverse effects that require the patient to contact the healthcare facility 
 (2.3.5).  
 6. Symptoms of events that require immediate discontinuation or oral chemotherapy 
 (2.3.6).  
 7. Procedures for handling medications in the home (2.3.7).    
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 8. Procedures for handling body secretions and waste in the home (2.3.8).  
All of the above standards are ASCO/ONS guidelines unless otherwise indicated (Neuss  et al., 
2017). 
ASCO/ONS guidelines sections 3.3. Identify the steps for proper verification prior to dispensing 
and administering: 
 1.  Orders for chemotherapy are signed by approved, licensed independent practitioners 
 who are determined to be qualified by the health care facility (3.3). 
 2. A licensed pharmacist verifies all orders before administration or dispensing of 
 chemotherapy (3.10). 
 3. A second person- a practitioner approved by health care facility to prepare or 
 administer chemotherapy - performs three independent verifications (3.11). 
 4. Before preparation, a second person - practitioner approved by the healthcare facility 
 to prepare or administer chemotherapy - independently verifies (3.11.1). 
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Appendix F 
Timeline  
Task 
2017 2018 
A M J J A S O N D J F M A M 
Engage Staff                
Project Approval                
Submit Ch 1-3 to Project Chair                
Submit Ch. 1-3 to committee               
Proposal Defense               
Ongoing Education: MD, PA, 
RN, PharmD 
              
Briefing Key Leaders & Staff               
Develop Data Base               
Intervention: Implement at SMC 
(10/1/2017) 
              
Collect Data                
Enter Data                
Analyze Data               
Interpret Data               
Final defense 
(3/16/2018) 
              
Graduation               
Prepare & Submit Dissemination 
Findings 
              
 
  
62 
Appendix G 
SMC Pharmacy Hormonal Exclusion Process 
Oral Antineoplastic Cytotoxic Chemotherapy Process 
Straub Medical Center oral antineoplastic cytotoxic chemotherapy process requires the 
oncologist or specialist review prior to continuation of therapy in the hospital 
 
Hawai‘i Pacific Health categorizes hazardous drugs into three categories per NIOSH: 
1. Hazardous cytotoxic 
2. Hazardous non-cytotoxic 
3. Reproductive risk 
At this time, the oral chemotherapy process applies only to hazardous cytotoxic antineoplastic 
agents. 
 
Pharmacists will refer to the HPH Hazardous Drug List and/or the NIOSH 2016 Hazardous Drug 
List (posted on the Pharmacy intranet) to categorize the oral agent 
• If the oral medication was recently approved by the FDA, the pharmacist will refer to 
 UptoDate (Lexicomp) and AHFS (links available on the Pharmacy Intranet) 
  
• If categorized as “antineoplastic” or AHFS category 10:00 Antineoplastic, the oral agent 
 will follow the Oral Antineoplastic Chemotherapy workflow 
 http://ahfs.ashp.org/drug-assignments.aspx 
 
Oral Hormonal Agents: Guidelines 
Hormonal agents (Antiandrogens, Aromatase Inhibitors, Selective Estrogen Receptor 
Modulators) will be excluded from the oral chemotherapy physician (oncologist or specialist) 
approval process with the exceptions below. 
• The pharmacist will screen for criteria and follow the oral chemotherapy workflow 
 process 
• No change to the oral chemotherapy medication administration process and notification 
 to 6th floor RN 
Class Criteria 
Antiandrogens May continue in hospital without oncologist/specialty prescriber approval 
unless: 
-Bicalutamide dose greater than 50mg daily 
• Larger than commonly recommended doses for non-formulary 
medications 
• Jaundice and/or ALT greater than 2 times the upper limit of normal 
• QT prolongation 
Aromatase 
Inhibitors 
May continue in hospital without oncology/specialty prescriber approval 
unless: 
-Anastrozole dose greater than 1mg daily 
-Exemestane dose greater than 25mg daily 
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-Letrozole doses greater than 2.5mg daily 
• Larger than commonly recommended doses for non-formulary 
medications 
• Pregnant or breastfeeding 
• Acute thrombo-embolism 
• New onset ischemic heart disease/angina 
Selective 
Estrogen 
Receptor 
Modulators 
May continue in hospital without oncology/specialty prescriber approval 
unless: 
-Tamoxifene dose greater than 40mg daily 
-Raloxifene dose greater than 60mg daily 
• Patient prescribed warfarin 
• Acute thrombo-embolism 
• Larger than commonly recommended doses for non-formulary 
medications 
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Appendix H 
Updated Algorithm with Hormonal Carve Out (Final Version)  
 
 
 
Inpatient Oral 
Antineoplastic 
Is it one of the                    
following hormonal agents? 
Antiandrogens, Aromatase 
inhibitor, or Selective estrogen 
receptor modulators? 
Yes No
Request Pharmacy 
consult for oral 
cyotoxic medication 
eval. DO NOT order 
med 
6th Floor RPh 
receives consult, if 
night/eve follow up 
for next day 
Is oral med for 
Oncology 
indication?
YesConsult Oncology 
Communication 
with original 
prescriber and 
documentation 
Oncologist orders 
oral medication
Pharmacy 
dispense 
medication
No Is prescriber outside HPH? Yes
RPh Consult 
Straub specialty  
Communication 
with original 
prescriber and 
documentation 
No
RPh contact 
original prescriber 
and document 
Specialty 
prescriber orders 
oral medication 
Pharmacy 
dispense 
medication
1st dose Oral 
Antineoplastic 
Administration 
RN to contact 6th 
Floor Nursing 
Charge RN 352- 
7801 (cell)
                         
Charge RN to 
review orders 
Chemo Competent RN administer 1st 
dose.                                                                     
1.Patient education                                                     
2. Off unit education                                                 
3. Documentation
Antiandrogens                                              
-Bicaltamide dose > 50mg daily                                      
-Jaundice and/or ALT > 2x upper 
limit normal                              
-QT prolongation                
-Larger than commonly 
recommended dose for 
non-formulary 
Aromatase Inhibitors 
-Anastrozole dose > 1mg daily                     
-Exemestane dose > 25mg daily 
-Letrozole dose > 2.5mg daily 
-Pregnant/breastfeeding      
-Acute thrombo-embolism     
-New onset ischemic heart 
disease/angina                  
-Larger than commonly 
recommended dose for 
non-formulary 
Prescribe med without 
Oncologist/ Specialty 
prescriber approval 
unless one of the 
following: 
Selective Estrogen Receptor 
Modulators                  
-Tamoxifene dose >40 mg daily 
-Raloxifene dose >60 mg daily 
-Pt prescribed warfarin         
-Acute thrombo-embolism 
-Larger than commonly 
recommended dose for 
non-formulary 
Request Pharmacy 
consult for oral 
cyotoxic medication 
eval. 
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Appendix I 
Updated Algorithm with Pharmacy Review (Version 2) 
 
 
Inpatient Oral Antineoplastic 
Hospitalist Request Pharmacy consult 
for oral cyotoxic medication eval. DO 
NOT order med 
6th Floor RPh receives 
consult, if night/eve follow up 
for next day 
Is patient 
Oncology patient?Yes No
Consult Oncology 
PA
Communication 
and 
documentation 
Oncologist orders 
oral medication
Pharmacy 
dispense 
medication
Is prescriber 
outside HPH? Yes
No
RPh contact 
prescriber and 
document 
RPh Contact 
Straub specialty  RPh discuss with 
Hospitalist
Hospitalist orders 
oral medication 
Pharmacy 
dispense 
medication
Specialty 
prescriber orders 
oral medication 
Oral 
Antineoplastic 
Administration 
RN to contact 6th 
Floor Nursing 
Charge RN 352- 
7801 (cell)
Charge RN to 
review orders 
Chemo Competent RN administer 1st 
dose.                                                                     
1.Patient education                                                     
2. Off unit education                                                 
3. Documentation
Hospitalist 
comfortable 
prescribing?
Yes
No
Communication 
and 
documentation 
OR
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Appendix J 
SMC Pharmacy Internal Oral Chemotherapy Process  
 
 
	 Inpatient	Oral	Antineoplastic	drug	
MD	consult	or	enters	the	order	
RPH	assessment:	
Check	NIOSH	list	or	UptoDate	
• If	AHFS	category	10	–	consider	oral	
cytotoxic	agent	
• Not	oral	hormonal	antineoplastic	
agent		
OR	
• Oral	hormonal	agent	not	within	
dosing	guidelines	or	with	risk	factors	
RPH	assessment:	
If	oral	hormonal	agent	(antiandrogen,	
aromatase	inhibitor,	SERM)	
Refer	to	dosing	guidelines	and	
adverse	effects	
If	within	parameters,	MD	may	order	
Oncology	indication	
Consult	oncology	PA	or	oncologist	
Non-oncology	indication	
Do	not	verify	the	order	in	Epic	work	queue	
• Notify	floor	pharmacist	
• 6th	floor	RPh	will	help	assess	oncology	indication	
Verify	the	order	in	Epic	work	queue	
Dispense	medication	
Notify	6th	floor	charge	RN	352-7801	
MD	to	discuss	with	specialist	re:	
continuation	of	medication	
MD	to	enter	order	in	Epic	
Verify	the	order	in	Epic	work	queue	
Dispense	medication	
Notify	6th	floor	charge	RN	352-7801	
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Appendix K 
Oral Chemotherapy EMR BPA Process  
o A BPA alert will fire when the pharmacist verifies an oral antineoplastic order as a 
reminder (AHFS class 10.00 - antineoplastic agents).   
o This alert should not fire for non-cytotoxic hazardous or reproductive risk hazardous 
drugs. 
o The BPA should trigger the pharmacist to verify the proper oral chemotherapy 
procedures (posted on pharmacy intranet). 
o If hormonal agent: review carve out guidelines - verify order if within guidelines, then 
notify the nurse that 6th chemotherapy-competent nurse must administer 1st dose.  
o If oral cytotoxic drug - leave in work queue with follow up for floor pharmacist.  
o All oral cytotoxic medication tablet/capsules should be labeled with "chemotherapy" 
sticker as well as a sticker on the outer bag.   
o Floor pharmacist assisting with facilitating, clarifying, and communicating oral chemo 
process will document short note in EMR record. Working on developing a note 
template to communicate with all providers. 
 
 
